Compare IIPR & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IIPR | SRPT |
|---|---|---|
| Founded | 2016 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2016 | 2000 |
| Metric | IIPR | SRPT |
|---|---|---|
| Price | $54.50 | $17.66 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 7 | 24 |
| Target Price | ★ $61.45 | $21.64 |
| AVG Volume (30 Days) | 385.7K | ★ 2.5M |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | ★ 13.93% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 2.39 | ★ 2.99 |
| Revenue | $265,955,000.00 | ★ $2,198,237,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.40 | N/A |
| P/E Ratio | $22.87 | ★ $6.08 |
| Revenue Growth | N/A | ★ 15.58 |
| 52 Week Low | $44.58 | $14.68 |
| 52 Week High | $65.38 | $24.68 |
| Indicator | IIPR | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 55.64 | 46.38 |
| Support Level | $54.00 | $16.51 |
| Resistance Level | $57.85 | $18.26 |
| Average True Range (ATR) | 1.26 | 0.93 |
| MACD | 0.49 | 0.14 |
| Stochastic Oscillator | 94.01 | 39.89 |
Innovative Industrial Properties Inc is a real estate investment trust focused on the acquisition, ownership and management of specialized industrial and commercial properties in the United States. Its properties are prominently leased to state-licensed operators for their regulated cannabis facilities. The company conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by its Operating Partnership, directly or through subsidiaries. Its segments are: Cannabis Portfolio and Life Science Portfolio, with the majority of revenue coming from the Cannabis Portfolio segment, which involves acquiring, developing, and leasing real estate to regulated cannabis operators on long-term triple-net leases.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.